Spectral AI, Inc. (MDAI) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Spectral AI, Inc. is an emerging growth company and smaller reporting company focused on predictive medical diagnostics, specifically the DeepView® Wound Imaging System for burn wounds and diabetic foot ulcers. The company currently generates revenue primarily through research and development contracts with U.S. government agencies, notably the Biomedical Advanced Research and Development Authority (BARDA) and the Medical Technology Enterprise Consortium (MTEC). It has not yet generated product revenue.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $7.48 million | $13.80 million | $4.25 million | $9.33 million |
| Gross Profit | $3.31 million | $6.26 million | $1.79 million | $3.97 million |
| Gross Margin | 44.3% | 45.3% | 42.1% | 42.6% |
| Operating Loss | $(2.44) million | $(4.59) million | $(2.99) million | $(5.89) million |
| Net Loss | $(2.86) million | $(6.07) million | $(3.07) million | $(6.68) million |
| Cash and Equivalents | $6.88 million (as of June 30, 2024) | |||
| Total Debt (Notes Payable) | $8.00 million (as of June 30, 2024) | |||
| Accumulated Deficit | $(38.86) million (as of June 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 75.9% quarter-over-quarter and 48.0% year-to-date, driven by increased activity under the Project BioShield (PBS) BARDA contract and other government awards.
- Debt Financing: The company significantly increased its debt load, entering into a Standby Equity Purchase Agreement (SEPA) with Yorkville. As of June 30, 2024, notes payable totaled $8.0 million, compared to $0.4 million at year-end 2023. This includes $7.0 million in Yorkville convertible notes and $1.0 million in related-party notes.
- Non-Operating Expenses: Other expenses increased due to borrowing-related costs ($0.7 million in Q2) and transaction costs associated with the Yorkville and B. Riley financing arrangements. Conversely, the change in fair value of warrant liabilities provided a gain of $0.35 million in Q2 2024, compared to a loss in the prior year.
- Liquidity: Cash balances increased from $4.79 million at December 31, 2023, to $6.88 million at June 30, 2024, primarily due to financing proceeds offsetting operating cash burn.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Resources: Management believes current cash, combined with proceeds from the PBS BARDA contract (up to $150 million total value), MTEC agreement, and available financing under the B. Riley ELOC and Yorkville SEPA, will fund operations for at least one year. However, the company may need to raise additional capital sooner if circumstances change.
- Nasdaq Compliance Risk: On June 3, 2024, the company received notice from Nasdaq regarding non-compliance with the minimum market value of listed securities requirement ($35.0 million). The company has 180 days (until December 2, 2024) to regain compliance. Failure to do so could result in delisting.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting, including communication failures regarding complex arrangements and inadequate controls for recording operating expenses and unbilled revenue. Remediation efforts are underway.
- Commercialization: The company expects to begin commercialization activities in the United Kingdom in the second half of 2024 following receipt of the UKCA mark for the burn indication.
Investor Verification Checklist
- Nasdaq Compliance Status: Verify if the company has met the $35.0 million market capitalization requirement to avoid delisting by December 2, 2024.
- Debt Covenants and Repayment: Review the terms of the Yorkville convertible notes, specifically the monthly installment payments ($1.75 million principal + premium) and the 18% default interest rate.
- Government Contract Reliance: Assess the risk of revenue concentration, as one U.S. government agency (BARDA) accounted for 94% of revenue in Q2 2024.
- Internal Control Remediation: Monitor progress on fixing material weaknesses in financial reporting controls to ensure future financial statement reliability.
- Commercialization Timeline: Track the progress of UK commercialization and FDA clearance for the DeepView system to evaluate the transition from contract-based to product-based revenue.